KeyZell has developed OPS (Oncology Precision System), an intelligence Artificial solution that determines the best combination of therapies against breast and lung cancer through a machine learning system. This tool makes it easier for oncologists to select the most appropriate treatment for each patient, taking into account their individual genetic characteristics.

KEYZELL OPS, with 89% efficacy, is the only system of precision medicine for oncological use focused on treatment and patient care. In addition, it identifies patterns and makes predictions contemplating up to 112 biomarkers, helping in the prediction of the best personalised treatment that guarantees the highest survival rate at 5 years.

For its selection, the tool takes into account variables such as clinical analysis data, the patient's molecular DNA profile, the IHC (immuno-histochemical) profile, effectiveness, toxicity, etc.

The same treatment is often applied to patients with the same type of cancer, however, there are groups of patients who respond markedly differently.  Therefore, the startup intends to continue developing this pioneering system worldwide and lead the biomedical revolution of precision medicine with KEYZELL OPS.

Iván Románico, head of oncology at the Ángeles Puebla Hospital, says: "We are witnessing the future of precision medicine with great enthusiasm and responsibility. Thanks to this type of tool, oncologists offer patients a more effective solution adjusted to their individual characteristics that undoubtedly has an impact on their quality of life."

"We want KEYZELL OPS to be the reference personalized treatment service for cancer in the field of precision medicine.  With this tool, our goal is to reverse the mortality figures of this disease and make them more hopeful year after year," says José de Corral, CEO of KeyZell.

About KeyZhim

KeyZell is formed by a multidisciplinary group of professionals from various fields, researchers from recognized centers of high prestige such as the University of Seville, the University of Malaga, or Imperial College London, engineers with management experience in large international projects, and senior professionals from the pharmaceutical, legal and business sectors. The company is also backed by a highly qualified team of advisors, not only in the medical or scientific area but also in intellectual property, legal or strategic issues.

Currently, KeyZell is working on several lines of research, on the one hand, a new first-line treatment against some types of tumors, pending the start of the clinical trial in phase I / IIa, a pre-clinical phase treatment to prevent metastasis. On the other hand, it develops the innovative artificial intelligence system KEYZELL OPS, of which it already has its industrial license, and which aims to be the future of precision medicine in oncology, and which starts from the search for patterns and personalized treatments for those cancer patients who do not respond to treatments, offering the most appropriate treatment for cancer,  in the right order and at the most appropriate time according to the characteristics of each patient.

Recently the startup has been awarded by the Isaac Peral National Awards for Research, Science and Innovation granted by the European Association of Economy and Competitiveness (AEDEEC), and has been recognized by the British magazine Health Tech World as one of the 50 best innovative companies in technology in the health sector in 2022.